ProCE Banner Activity

Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients


Downloadable slideset covering the latest advancements in managing low-risk myelodysplastic syndromes.

Released: May 31, 2024

Expiration: May 30, 2025



Rami Komrokji

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Maximilian Stahl

Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb